Original articlePseudocystic Foveal Cavitation in Tamoxifen Retinopathy
Section snippets
Methods
This is an observational case series of 3 patients presenting to the Bascom Palmer Eye Institute. The University of Miami Institutional Review Board waived the need for approval based on the limited number of patients involved and the observational nature of the study. The study adhered to the tenets of the Declaration of Helsinki and was in accordance with HIPAA regulations and all federal and state laws.
Case 1
A 63-year-old Haitian woman presented for a second opinion on macular edema. She had not noticed any problem with her vision until 1.5 years prior to presentation, when on routine examination her optometrist could not correct her vision with glasses and sent her to a retina specialist. She was diagnosed with bilateral macular edema and given a single injection of bevacizumab in the right eye. By history, a fluorescein angiogram (FA) was not obtained. She experienced no change in vision from the
Discussion
The hallmark of tamoxifen ocular toxicity was previously thought to be crystalline retinopathy. This association was largely based on clinical findings in patients treated with high-dose tamoxifen. When given in excess of 120 mg daily, tamoxifen can lead to marked crystalline retinopathy and CME.15
Since the standard dose of tamoxifen was reduced to 20 mg daily, there have been fewer reports of clinically significant ocular toxicity. However, recent developments in ocular imaging technology have
Rishi R. Doshi, MD is a medical retina specialist. He received his medical degree from the University of California at San Diego, and completed his residency training at California Pacific Medical Center in San Francisco prior to pursuing a medical retina fellowship at the Bascom Palmer Eye Institute. He served as an Assistant Professor at the Bascom Palmer Eye Institute prior to accepting his current position at the Beaver Medical Group in Redlands, California.
References (40)
- et al.
Optical coherence tomography findings in tamoxifen retinopathy
Am J Ophthalmol
(2005) - et al.
Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy
Am J Ophthalmol
(2007) - et al.
Screening for ocular toxicity in asymptomatic patients treated with tamoxifen
Am J Ophthalmol
(1994) - et al.
Perifoveal muller cell depletion in a case of macular telangiectasia type 2
Ophthalmology
(2010) - et al.
Retinal crystals in type 2 idiopathic macular telangiectasia
Ophthalmology
(2011) - et al.
Muller cells in the healthy and diseased retina
Prog Retin Eye Res
(2006) - et al.
Tamoxifen retinopathy. A clinicopathologic report
Ophthalmology
(1981) - et al.
A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma
Eur J Cancer Clin Oncol
(1989) - et al.
Long-term tamoxifen citrate use and potential ocular toxicity
Am J Ophthalmol
(1998) - et al.
Intraocular penetration of tamoxifen
Ophthalmology
(2000)
Tamoxifen as a potential treatment of glioma
Anticancer Drugs
Clomiphene and anti-oestrogens for ovulation induction in PCOS
Cochrane Database Syst Rev
Tamoxifen-associated eye disease. A review
J Clin Oncol
The eyes have it! Tamoxifen maculopathy revisited: a case report
J Ocul Pharmacol Ther
Diagnostic & therapeutic challenges. Tamoxifen toxicity
Retina
Estrogen antagonist and development of macular hole
Korean J Ophthalmol
Optical coherence tomography in tamoxifen retinopathy
Breast Cancer Res Treat
Microcystoid maculopathy associated with tamoxifen use diagnosed by high-resolution Fourier-domain optical coherence tomography
Retin Cases Brief Rep
Early detection of tamoxifen-induced maculopathy in patients with low cumulative doses of tamoxifen
Ophthalmic Surg Lasers Imaging
Cited by (55)
En face OCT analysis of Bietti's crystalline dystrophy
2024, American Journal of Ophthalmology Case ReportsTamoxifen retinopathy: A comprehensive review
2024, Survey of OphthalmologyTamoxifen retinopathy
2023, Survey of OphthalmologyTamoxifen-induced toxic maculopathy at low cumulative dose : The value of multimodal imaging
2022, Journal Francais d'OphtalmologieRetinal toxicities of systemic anticancer drugs
2022, Survey of OphthalmologyCitation Excerpt :In a histopathological study223 TAR lesions were localized in the nerve fiber and inner plexiform layers, similar to the crystals in MacTel2. This also supports the fact that the two diseases may be having a common pathogenesis involving Müller cell dysfunction.263,109 Doshi and cowokers109 also pointed out that crystal deposits in TAR were highlighted on blue light fundus reflectance (BLR) imaging that shows areas with macular pigment loss449 suggestive of Müller cell dysfunction.
Rishi R. Doshi, MD is a medical retina specialist. He received his medical degree from the University of California at San Diego, and completed his residency training at California Pacific Medical Center in San Francisco prior to pursuing a medical retina fellowship at the Bascom Palmer Eye Institute. He served as an Assistant Professor at the Bascom Palmer Eye Institute prior to accepting his current position at the Beaver Medical Group in Redlands, California.
Supplemental Material available at AJO.com.
Rishi R. Doshi is currently at Beaver Medical Group, Redlands, California.
Brian T. Kim is currently at Harvard Eye Associates, Laguna Hills, California.